Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Review

Clinical Trial

Randomized Controlled Trial

Comparative Study

Multicenter Study

Clinical Trial, Phase III

Clinical Trial, Phase II

Research Support, N.I.H., Extramural

Publication Year

From

Quick links

Individual year

2021

2008

2007

2006

2005

2004

2002

2001

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Purinergic P2 Receptor Agonists""[mesh_terms]

14 Results

Searching titles within these results

Diquafosol tetrasodium: a novel dry eye therapy.

Donald J Kellerman, Ben Yerxa, Kelly K Nichols

Expert opinion on investigational drugs 2004;13(1):47-54

Full Text

Abstract

A molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 activation.

Jeremy E Purvis, Manash S Chatterjee, Lawrence F Brass, Scott L Diamond

Blood 2008;112(10):4069-79

Free Full Text

Abstract

Plant natural products as source of new P2 receptors ligands.

Betina Quintanilha Magalhães, Robson Xavier Faria, Roberta Tosta Diogo, Paulo Anastácio Furtado Pacheco

Fitoterapia 2021;146():104709

Full Text

Abstract

Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes.

Iliana Moreschi, Santina Bruzzone, Robert A Nicholas, Floriana Fruscione, Laura Sturla, Federica Benvenuto, Cesare Usai, Sabine Meis, Matthias U Kassack, Elena Zocchi, Antonio De Flora

The Journal of biological chemistry 2006;281(42):31419-29

Free Full Text

Abstract

Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors.

Marco Idzko, Stefan Dichmann, Davide Ferrari, Francesco Di Virgilio, Andrea la Sala, Giampiero Girolomoni, Elisabeth Panther, Johannes Norgauer

Blood 2002;100(3):925-32

Free Full Text

Abstract

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.

Robin R Deterding, Lisa M Lavange, Jean M Engels, Dave W Mathews, Sarah J Coquillette, Alan S Brody, Steve P Millard, Bonnie W Ramsey

American journal of respiratory and critical care medicine 2007;176(4):362-9

Full Text

Abstract

Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells.

Cinzia Pizzirani, Davide Ferrari, Paola Chiozzi, Elena Adinolfi, Dorianna Sandonà, Erika Savaglio, Francesco Di Virgilio

Blood 2007;109(9):3856-64

Free Full Text

Abstract

Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5'-O-(alpha-boranotriphosphate) analogues.

D Ecke, M E Tulapurkar, V Nahum, B Fischer, G Reiser

British journal of pharmacology 2006;149(4):416-23

Free Full Text

Abstract

Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.

M V Mundasad, G D Novack, V E Allgood, R M Evans, J C Gorden, B R Yerxa

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2001;17(2):173-9

Full Text

Abstract

Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

J Tauber, W F Davitt, J E Bokosky, K K Nichols, B R Yerxa, A E Schaberg, L M LaVange, M C Mills-Wilson, D J Kellerman

Cornea 2005;23(8):784-92

Full Text

Abstract

Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.

Donald Kellerman, Andrea Rossi Mospan, Jean Engels, Amy Schaberg, Joann Gorden, Lynn Smiley

Pulmonary pharmacology & therapeutics 2008;21(4):600-7

Full Text

Abstract

P2 purinergic receptors of human eosinophils: characterization and coupling to oxygen radical production.

D Ferrari, M Idzko, S Dichmann, D Purlis, C Virchow, J Norgauer, P Chiozzi, F Di Virgilio, W Luttmann

FEBS letters 2001;486(3):217-24

Free Full Text

Abstract

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.

Kenneth Schwartz, Alex Malinin, Alex Pokov, Malcolm Spergling, Anthony Defranco, Dianne Schwartz, Ehtisham Mahmud, Dan Atar, Victor Serebruany

Thrombosis research 2007;119(3):277-84

Full Text

Abstract

Treatment of airway mucus hypersecretion.

Duncan F Rogers, Peter J Barnes

Annals of medicine 2006;38(2):116-25

Full Text

Abstract

Results: 1 – 14 / 14

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Purinergic P2 Receptor Agonists""[mesh_terms]

Diquafosol tetrasodium: a novel dry eye therapy.

A molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and P2Y1 activation.

Plant natural products as source of new P2 receptors ligands.

Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor in human granulocytes.

Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors.

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.

Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells.

Opposite diastereoselective activation of P2Y1 and P2Y11 nucleotide receptors by adenosine 5'-O-(alpha-boranotriphosphate) analogues.

Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects.

Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.

Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.

P2 purinergic receptors of human eosinophils: characterization and coupling to oxygen radical production.

Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.

Treatment of airway mucus hypersecretion.

Results for
""Purinergic P2 Receptor Agonists""[mesh_terms]